Options update: Respironics volatility flat into PHG acquiring it for $5.1 billion

Posted Dec 21st 2007 10:43AM by Paul Foster
Filed under: Genentech Inc (DNA), Options

Respironics (NASDAQ: RESP) will be acquired by Philips (NYSE: PHG) for $66 in cash per cash. RESP, a provider of treatments for Obstructive Sleep Apnea, closed at $53.61. RESP over all option implied volatility of 28 is near its 26-week average according to Track Data, suggesting non-directional risk.

Genentech (NYSE: DNA) closed at $67.96. DNA will report EPS on January 14th. DNA January option implied volatility of 30 is above its 26-week average of 26 according to Track Data, suggesting larger price risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Tags: dna, genentech, inthenews, Obstructive Sleep Apnea, ObstructiveSleepApnea, option implied volatility, OptionImpliedVolatility, phg, Philips, resp, Respironics